Name a sleep aid and I can describe the specific type of hangover it gives me. The morning after overdoing melatonin by even five milligrams, I wake up to pressure at my temples and mental fog so thick that conversation is difficult. Post-Benadryl fatigue feels as if each of my cells are begging me to get back in bed. If I take too much Ambien, it is like I never woke up at all: I float around half-sentient, reanimating just in time for dinner.
Enter cannabidiol, or CBD, one of many chemical compounds produced by cannabis, and the latest darling of the wellness world.
Sativa Investments (NEX:SATI) is the UK’s first medicinal cannabis investment vehicle. After investing in two North American businesses, it is now progressing a UK seed to consumer investment strategy with 100% ownership of businesses involved in the production, testing and compliance, research & development including pharmacology, commercialisation and sales & marketing of medicinal cannabis and cannabidiol products. Two UK businesses, George Botanicals and PhytoVista Laboratories, are already fully operational. The Company intends to add a 7.5-acre cannabis growing and processing facility and has already executed an option agreement over an optimum site.